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Abstract
OBJECTIVE: To analyse the expression of SIRT1 in synovial tissues and cells of patients with
rheumatoid arthritis (RA) and to study the function of SIRT1 in inflammation and apoptosis in RA.
METHODS: Levels of SIRT1 expression were analysed in synovial tissues and cells from patients with
RA by real-time PCR and western blotting before and after stimulation with toll-like receptor ligands,
tumour necrosis factor α (TNFα) and interleukin 1β (IL-1β). Immunohistochemistry was used to study
the localisation of SIRT1. Fluorescence activated cell sorting analysis was performed to investigate the
effect of SIRT1 on apoptosis. Peripheral blood monocytes and rheumatoid arthritis synovial fibroblasts
(RASFs) were transfected with wild-type or enzymatically inactive SIRT1 expression vectors or with
siRNA targeting SIRT1. Cytokine analysis of IL-6, IL-8 and TNFα were performed by ELISA to study
the role of SIRT1 on proinflammatory mediators of RA. RESULTS: SIRT1 was found to be
constitutively upregulated in synovial tissues and cells from patients with RA compared to osteoarthritis.
TNFα stimulation of RASFs and monocytes resulted in further induced expression levels of SIRT1.
Silencing of SIRT1 promoted apoptosis in RASFs, whereas SIRT1 overexpression protected cells from
apoptosis. Inhibition of SIRT1 enzymatic activity by inhibitors, siRNA and overexpression of an
enzymatically inactive form of SIRT1 reduced lipopolysaccharide-induced levels of TNFα in
monocytes. Similarly, knockdown of SIRT1 resulted in a reduction of proinflammatory IL-6 and IL-8 in
RASFs. CONCLUSION: The TNFα-induced overexpression of SIRT1 in RA synovial cells contributes
to chronic inflammation by promoting proinflammatory cytokine production and inhibiting apoptosis.
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 ABSTRACT 
Objective: 
To analyze the expression of SIRT1 in synovial tissues and cells of rheumatoid arthritis (RA) 
patients and to study the function of SIRT1 in inflammation and apoptosis in RA. 
Methods: 
Levels of SIRT1 expression were analyzed in synovial tissues and cells from RA patients by 
Real-time PCR and Western blotting before and after stimulation with Toll-like receptor 
(TLR) ligands, tumor-necrosis factor alpha (TNF-α) and interleukin (IL)-1β. 
Immunohistochemistry was used to study the localization of SIRT1. FACS analysis was 
performed to investigate the effect of SIRT1 on apoptosis. Peripheral blood monocytes and 
RA synovial fibroblasts (RASF) were transfected with wild type or enzymatically inactive 
SIRT1 expression vectors or with siRNA targeting SIRT1. Cytokine analysis of IL-6, IL-8 
and TNF-α were performed by ELISA to study the role of SIRT1 on proinflammatory 
mediators of RA. 
Results: 
SIRT1 was found to be constitutively upregulated in synovial tissues and cells from RA 
compared to osteoarthritis (OA) patients. TNF-α stimulation of RASFs and monocytes 
resulted in further induced expression levels of SIRT1. Silencing of SIRT1 promoted 
apoptosis in RASFs, whereas SIRT1 overexpression protected cells from apoptosis. Inhibition 
of SIRT1 enzymatic activity by inhibitors, siRNA and overexpression of an enzymatically 
inactive form of SIRT1 reduced lipopolysaccharide (LPS)-induced levels of TNF-α in 
monocytes. Similarly, knockdown of SIRT1 resulted in a reduction of proinflammatory IL-6 
and IL-8 in RASFs.  
Conclusion: 
The TNF-α induced overexpression of SIRT1 in RA synovial cells contributes to chronic 
inflammation by promoting proinflammatory cytokine production and inhibiting apoptosis.
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 INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterised by the destruction 
of joint cartilage and bone. Synovial hyperplasia and persistent synovial inflammation with 
infiltration of inflammatory immune cells into the synovial lining are hallmarks of RA.[1] 
Innate immunity was shown to be important for the development of chronic arthritis. 
Activation of Toll-like (TLR) and NOD-like receptors in synovial cells leads to the expression 
of several proinflammatory genes, such as interleukin-6 (IL-6) and tumor-necrosis factor 
alpha (TNF-α).[2, 3] We have previously reported the induction of the adipokine PBEF, also 
called Visfatin, upon stimulation of TLRs.[4] PBEF/Visfatin catalyses the rate-limiting step in 
the biosynthesis of nicotinamide-adenine-dinucleotide (NAD+).[5] By regulating intracellular 
NAD+ levels, PBEF/Visfatin influences the activity of a variety of NAD+ consuming 
enzymes, including the sirtuins (SIRT).[6, 7] 
SIRTs are a conserved family of NAD+ dependent histone deacetylases (HDAC) and mono-
ADP-ribosyltransferases that target histones, transcription factors, and coregulators to adapt 
gene expression to the cellular energy state.[8-10] In mammals seven sirtuin genes – SIRT1 to 
SIRT7 – have been identified. Among them, SIRT1 is best characterised so far and has been 
shown to regulate transcription factors such as p53 [11], members of the forkhead 
transcription factor FOXO family [12], the DNA repair factor Ku70 [13], NF-κB [14] and the 
transcriptional coactivator p300.[15] 
In lung cancer cell lines, SIRT1 was found to physically interact with and deacetylate the 
RelA/p65 subunit of NF-κB, thereby inhibiting its ability to interact with promoter regions of 
target genes to enhance transcription.[14] Hyperacetylation of lysine 310 of RelA/p65 
rendered NF-κB highly active, resulting in increased transcription of proinflammatory 
cytokines such as TNF-α and IL-1 in a myeloid SIRT1 knock out mouse model.[16] However, 
nicotinamide has been shown to reduce the production of proinflammatory cytokines as well 
as IL-10 in primary human macrophages, possibly via inhibiting sirtuins. [17]  
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The last years, SIRT1 gained much attention since its expression was shown to mediate 
longevity.[18] SIRT1 deacetylates the DNA repair factor Ku70 leading to inhibition of 
apoptosis. In addition, SIRT1 protected epithelial cells from p53-mediated apoptosis. [11, 19] 
Contrary to these findings, in HEK293 epithelial cells, SIRT1 augmented apoptosis in 
response to TNF-α [14], highlighting that SIRT1 might have different biological outcome 
depending on the apoptotic stimuli. 
So far, SIRT1 expression and function in the RA synovium has not been analysed. Therefore, 
in consideration of the mentioned controversial results on the influence of sirtuins on 
inflammation and apoptosis, we have analyzed the expression, regulation and function of 
SIRT1 in RA. We show overexpression of SIRT1 in synovial tissues from RA patients. In 
addition, SIRT1 is shown to decrease apoptosis in synovial cells and to promote 
proinflammatory cytokine production. 
 
 
 MATERIAL & METHODS 
Patients and tissue preparation 
Synovial tissue biopsy specimens were obtained from patients with RA and osteoarthritis 
(OA), after informed consent has been obtained (Department of Orthopedic Surgery, 
Schulthess Clinic, Zurich, Switzerland). All RA patients fulfilled the American College of 
Rheumatology criteria for classification of RA.[20] Synovial tissue specimens were digested 
and SFs were grown as previously described.[21] The patient characteristics used in this study 
are shown in Table 1.  
 
Table 1: Patient characteristics used in this study* 
 
 RA patients (n=39) 
OA patients 
(n=10) 
Healthy 
controls (n=6) 
Age, mean (range) years 62 (29-86) 76 (64-98) † 43 (29-64) § 
Sex, no. female/male 31/8 5/5 4/2 
Disease duration, mean (range) years 25 (3-50) NA NA 
Medications, no. taking/no. assessed    
    NSAIDs 12/39 3/10 0/6 
    DMARDs 31/39 0/10 0/6 
No. RF+ (>20 IU)/no. assessed 29/29 NA NA 
CRP, mean (range) mg/liter 14.4 (1.0-52.5) 6.9 (0.9-39.5) NA 
 
* NA = not assessed; NSAIDs = nonsteroidal antiinflammatory drugs; DMARDs = disease-
modifying antirheumatic drugs; RF = rheumatoid factor; CRP = C-reactive protein. 
† Patients with osteoarthritis (OA) were significantly older than patients with rheumatoid 
arthritis (RA) and healthy controls. 
§ Healthy controls were significantly younger than patients with OA and RA. 
 
 
Preparation of monocytes from peripheral blood 
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 Isolation of peripheral blood mononuclear cells (PBMC) from whole blood of healthy donors 
or patients with RA was performed using standard Ficoll density-gradient centrifugation (GE 
Healthcare, Otelfingen, Switzerland). Monocytes were separated by positive selection with 
CD14 MACS MicroBeads or, when used for stimulation or transfection experiments, by 
negative selection with MACS MicroBeads Kit II (Miltenyi Biotec, Bergisch Gladbach, 
Germany). 
 
Stimulation assays 
RASFs and primary peripheral monocytes from healthy individuals were plated in 12- and 24-
well plates  (5 x 104 and 3-5 x 105 cells/well) in 500 μl supplemented DMEM and RPMI, 
respectively, and stimulated for the indicated time points with the following agents: 300 ng/ml 
Pam3CSK4, 10 μg/ml poly(I:C) (both InvivoGen, San Diego, CA), 10 ng/ml 
lipopolysaccharide (LPS from Escherichia coli J5; List Biologicals, Campbell, CA), 10 ng/ml 
TNF-α, 1 ng/ml IL-1β (both R&D Systems, Abingdon, United Kingdom), 30 μM Sirtinol 
(Sigma, Buchs, Switzerland) or 9 μM EX-527 (Tocris Bioscience, Bristol, UK). 
 
Transfection experiments 
Monocytes from healthy volunteers and RASFs were transfected using AMAXA 
nucleofection kits VPA-1007 and VVPI-1002 (both Lonza, Cologne, Germany), respectively. 
For silencing experiments, 100 μM SIRT1 validated stealth siRNA or stealth control high GC 
siRNA (both Invitrogen, Basel, Switzerland) were used. For overexpression experiments, 1 μg 
of SIRT1 wild type, SIRT1 mutant (H363Y), empty pcDNA3.1(-) (mock) or no nucleic acid 
(untransfected) was used. pcDNA3.1-SIRT1-MYC/HIS wild type and the catalytically 
inactive mutant (H363Y) were described previously.[22] Transfected monocytes were further 
incubated at 37°C for 18-20 hours before stimulation with LPS for 8 hours, in presence or 
absence of 50 μM sc-514 (Sigma, Buchs, Switzerland). RASFs were transfected for 48 hours 
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 and subsequently stimulated with LPS or TNF-α for 24 hours (siRNA) or 40 hours (vectors). 
Successful transfection was confirmed by Real-time PCR using SIRT1 mRNA specific 
primers. 
 
Real-time polymerase chain reaction (PCR) 
Total RNA was isolated with the RNeasy Mini kit including treatment with RNase-free 
DNase (Qiagen, Hombrechtikon, Switzerland) and reverse transcribed using random 
hexamers and multiscribe reverse transcriptase (both Applied Biosystems, Rotkreuz, 
Switzerland). Non-reverse transcribed samples were used as negative controls. Quantification 
of SIRT1 and IL-6 mRNA was performed by TaqMan RT-PCR using the ABI Prism 7700 
Sequence Detection system (Applied Biosystems). The primer sequences are shown in Table 
2. The endogenous control 18S cDNA was used for correcting the results with the 
comparative threshold cycle (Ct) method for relative quantification as described by the 
manufacturer.  
 
Table 2: SYBR green primers used for Real-time PCR 
 
SIRT1 forward: 5’-GCG GGA ATC CAA AGG ATA AT-3’ 
SIRT1 reverse: 5’-CTG TTG CAA AGG AAC CAT GA-3’ 
IL-6 forward: 5’-CTC TTC AGA ACG AAT TGA CAA ACA A-3’ 
IL-6 reverse: 5’-GAG ATG CCG TCG AGG ATG TAC-3’ 
 
Enzyme linked immunoabsorbant assay (ELISA)  
Protein in cell supernatants was detected by ELISA with OptEIA Kits (BD Pharmingen, San 
Diego, CA) for TNF-α, IL-6 and IL-8 according to the manufacturer’s instructions. 
Absorption was measured at 450 nm and data were analysed using Revelation v4.22 software 
(Dynex Technologies, Denkendorf, Germany). 
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Immunohistochemistry 
Synovial tissues were fixed in paraformaldehyde and embedded in paraffin. Tissue sections 
were deparaffinized and pretreated with 10 mM citrate buffer, pH 6. After blocking 
endogenous peroxidase and nonspecific binding, slides were incubated with rabbit IgG 
(Jackson, Suffolk, UK) or rabbit-anti-human SIRT1 antibody (E104, 1:40, Abcam, 
Cambridge, UK) over night at 4°C. For double staining, 2 μg/ml mouse-anti-vimentin, mouse-
anti-CD68 antibodies (both Dako, Glostrup, Denmark) or mouse IgG (Jackson, Suffolk, UK) 
were added. Sections were incubated with biotinylated goat-anti-rabbit IgG and AP-
conjugated goat-anti-mouse antibodies (Jackson, Suffolk, UK) followed by incubation with 
HRP-conjugated streptavidin complex (ABC Kit, Vector laboratories, Peterborough, UK). 
SIRT1 positive cells were visualized using DAB-Nickel (Vector laboratories, Peterborough, 
UK). Vimentin or CD68 positive cells were visualized using Vector Red reagent. SIRT1 
single stained and IgG control slides were counterstained with Eosin. 
 
Immunoblotting 
For protein preparation, tissues and cells were lysed in RIPA buffer, boiled and mixed with 
Laemmli buffer.[23] Proteins were separated on SDS-polyacrylamide gels and transferred to 
Protran nitrocellulose membranes (Schleicher & Schüll, Dassel, Germany). Membranes were 
probed with anti-SIRT1 antibodies (E104, Abcam) and anti-α-tubulin (Sigma, Buchs, 
Switzerland), respectively, and detected with HRP-conjugated secondary antibodies using the 
ECL Western blotting detection system (Amersham Pharmacia Biotech, Piscataway, NJ). 
 
Fluorescence activated cell sorting (FACS) 
RASFs were transfected with siRNA or vectors as described above for 48 hours. Medium was 
changed and 24 hours later, cells were detached with Accutase (PAA Laboratories, Pasching, 
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Austria) and stained for AnnexinV and PI with the AnnexinV-FLUOS Staining Kit (Roche, 
Mannheim, Germany). Cells were subsequently analyzed on a FACSCalibur flow cytometer. 
Data were processed using CellQuest software (BD Biosciences, San Jose, CA).  
 
Statistical analysis  
Unpaired and paired t-tests or one-way ANOVA followed by Dunnett’s post test were used 
where appropriate for statistical evaluation of the data by GraphPad Prism 5.0 software. 
Values are presented as mean (SEM). p-values less than 0.05 were considered as significant. 
 
 RESULTS  
Elevated expression of SIRT1 in RA synovial tissues. 
To study the association of SIRT1 expression with chronic joint inflammation in RA, we 
compared SIRT1 protein levels in RA with noninflammatory OA synovial tissues. Western 
blot analysis revealed higher expression of SIRT1 protein in whole synovial tissue and 
cultured SFs from joints of patients with RA compared to OA (Figure 1A). Real-time PCR 
analysis showed 5.2 fold higher levels of SIRT1 mRNA in SFs from RA compared to OA 
patients (p<0.01). Additionally, levels of SIRT1 mRNA were 2.2 times higher in peripheral 
blood monocytes from RA patients compared to healthy volunteers (p<0.01; Figure 1B). 
 
Localization of SIRT1 expression in RA synovial tissue sections. 
To further analyze the expression of SIRT1 in synovial tissue sections from patients with RA, 
we performed immunohistochemistry. Pronounced expression of nuclear SIRT1 protein was 
found in the lining and sublining layers, but also in perivascular areas (Figure 2A). Double 
staining with SIRT1 and vimentin or CD68 showed the expression of SIRT1 in vimentin 
positive SFs as well as in CD68 positive monocytes/macrophages (Figures 2B and C). 
 
SIRT1 expression is induced upon stimulation with TNF-α. 
To analyze the influence of activated TLR pathways and IL-1β on SIRT1 expression, RASFs 
were treated with TLR ligands and IL-1β for 24 hours. Real-time PCR analysis revealed no 
changes in the levels of SIRT1 mRNA. However, stimulation of RASFs with TNF-α revealed 
a modest induction of SIRT1 mRNA (Figure 3A). Time course analysis showed increased 
levels of SIRT1 mRNA already after 1 and 4 hours upon TNF-α (supplementary Figure 1). 
Western blot analysis of TNF-α stimulated RASFs confirmed induction of SIRT1 protein 
expression after 48 hours (Figure 3B). Similarly to RASFs, activation of monocytes by TNF-α 
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 resulted in a 4.8-fold increase of SIRT1 mRNA levels after 4 hours of stimulation (p<0.05), 
whereas at 24 hours SIRT1 mRNA levels were back to baseline (Figure 3C). 
 
SIRT1 mediates apoptosis resistance in RASF. 
As SIRT1 has been shown to prolong cellular life span and as spontaneous apoptosis is 
known to be reduced in activated RASFs, we assessed the effect of SIRT1 on apoptotic cell 
death. RASFs were transfected with siRNA and expression vectors as described above. SIRT1 
silenced RASFs showed an increase of 48 and 41 % in the number of AnnexinV positive 
(p<0.02) and PI positive (p<0.03) cells, respectively. When RASFs were transfected to 
overexpress a vector encoding SIRT1, cells were less susceptible to apoptosis, displayed by a 
decrease in AnnexinV positive (49 %, p<0.05) and PI positive (46 %, p<0.05) RASFs (Figure 
4). These results suggest that the constitutive overexpression of SIRT1 in RASFs may lead to 
a prolonged lifespan of these cells. 
 
SIRT1 positively affects production of the proinflammatory mediators IL-6 and IL-8 in 
RASFs. 
We next assessed whether SIRT1 also has a direct impact on the inflammatory phenotype of 
RASFs. Therefore, the production of the proinflammatory cytokine IL-6 was analysed in LPS 
stimulated RASFs after transfection with a SIRT1 expression vector. Interestingly, 
overexpression of SIRT1 increased the production of LPS induced IL-6 compared to mock 
transfected RASFs by 56 % (p<0.05). This enhancing effect on IL-6 production was not seen 
when cells were transfected with a mutant form of SIRT1 (H363Y, Figure 5A). Similar results 
were obtained by stimulation with TNF-α instead of LPS (supplementary Figure 2). Analysis 
of SIRT1 mRNA levels revealed successful overexpression in both wild type and mutant 
SIRT1 transfected RASFs (p<0.05, supplementary Figure 3A). 
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 Accordingly, when RASFs were transfected with control or SIRT1 specific siRNA for 48 
hours, there was a significant reduction of both basal and LPS stimulated expression of IL-6 
and IL-8 after knockdown of SIRT1. Basal IL-6 and IL-8 production was diminished by 37 ± 
11 % and 47 ± 21 % (p<0.05), respectively, whereas LPS induced IL-6 and IL-8 levels were 
reduced by 40 ± 15 % and 70 ± 14 % (p<0.05), respectively (Figure 5B). Also, IL-6 and IL-8 
mRNA levels were reduced after SIRT1 knockdown, arguing against purely translational 
effects of SIRT1 (supplementary Figure 4). Successful knockdown of SIRT1 was confirmed 
by Real-time PCR (supplementary Figure 3B).  
 
SIRT1 increases production of TNF-α in monocytes. 
As monocytes produce only low amounts of IL-6, we measured the production of TNF-α, a 
major cytokine involved in the pathogenesis of RA. Freshly isolated monocytes were 
subjected to transfection with SIRT1 expression vectors or siRNA as described above and 
subsequently stimulated with LPS. Consistent with the results obtained in RASFs, monocytes 
overexpressing wild type SIRT1 showed an increase of 36 % in TNF-α production compared 
to mock transfected cells (p<0.01). This induction in TNF-α levels was not seen when 
monocytes were transfected with the mutant form of SIRT1 (H363Y, Figure 5C). Non-
stimulated cells did not produce detectable amounts of TNF-α. Further confirmation that 
SIRT1 signaling regulates the LPS induced production of TNF-α in monocytes was obtained 
by specific down-regulation of SIRT1 using siRNA. Measurement of LPS induced TNF-α in 
the cell culture supernatants indicated a significant decrease of 31 % (p<0.02) (Figure 5D). 
Real-time PCR analysis was used to verify successful transfections (p<0.02, supplementary 
Figures 3C and D). 
 
Enzymatic sirtuin inhibitors decrease TNF-α production in monocytes. 
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 As we found a prominent difference in the levels of TNF-α between wild type and mutant 
SIRT1 transfected monocytes, we tested the effects of commercially available SIRT inhibitors 
on TNF-α production. Monocytes were stimulated with LPS in presence of the SIRT1 specific 
enzymatic inhibitor EX-527 and the levels of TNF-α were measured. Consistent with our 
previous results, EX-527 reduced the expression of TNF-α by 37 ± 17 % (p<0.01, Figure 6A). 
Furthermore, we used the pan sirtuin inhibitor Sirtinol to block the activity of all the sirtuins. 
Interestingly, also Sirtinol reduced the LPS induced TNF-α production by 49 ± 9 % (p<0.01), 
suggesting that the sirtuin family overall has proinflammatory effects in monocytes (Figure 
6B).  
 
The proinflammatory activity of SIRT1 is mediated through NF-κB dependent 
pathways. 
NF-κB is known to be essential for cytokine signaling in RA.[24] Additionally, SIRT1 was 
shown to affect expression of NF-κB dependent genes, such as p53 and Bcl-2.[14, 25] We 
assessed whether the effects of SIRT1 in monocytes are dependent on NF-κB by using an 
inhibitor of IKK-2, sc-514. When SIRT1 was overexpressed in monocytes, LPS induced 
TNF-α levels were increased as shown before. This SIRT1 dependent increase was 
completely blocked by treatment with the IKK-2 inhibitor sc-514, suggesting that SIRT1 acts 
via a NF-κB dependent mechanism (Figure 7). 
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 DISCUSSION 
SIRT1, a member of the NAD+ dependent class III HDACs, deacetylates both histones and 
non-histone targets.[10] Thereby, SIRT1 controls a broad range of cellular processes, 
including cell survival and inflammation.[19, 26] Interestingly, SIRT1 was shown to be 
induced by calorie restriction (CR), thereby connecting SIRT1 with the beneficial effects of 
CR on longevity and age-related disorders such as diabetes.[27] In addition, increased levels 
of SIRT1 were found in diseases such as neurodegeneration, cancer and experimental 
autoimmune encephalomyelitis.[28] We have analysed SIRT1 expression and found SIRT1 to 
be overexpressed in RA synovial tissues as compared to OA. SIRT1 is expressed in synovial 
fibroblasts and monocytes/macrophages, suggesting that in joints SIRT1 is predominantly 
expressed in tissue resident cells. 
The regulation of SIRT1 expression is incompletely understood. Different effects of cytokines 
on SIRT1 expression have been described. Both the cytokines IL-1β and interferon-γ have 
been shown to reduce the expression of SIRT1 in rat islets [29], whereas TNF-α induced 
SIRT1 expression in human vascular smooth muscle cells.[30] Here we show that the basal 
overexpression of SIRT1 in RA can be further induced upon stimulation with TNF-α, a major 
cytokine found in joints of RA patients. However, SIRT1 expression was not influenced by 
stimulation with TLR ligands and IL-1β in vitro, suggesting that TLR pathways do not 
directly regulate SIRT1 expression.  
SIRT1 has emerged as a key anti-aging protein in different experimental models, such as in 
Sacharomyces cerevisiae, in sirt1-null mice as well as in various in vitro cell cultures.[11, 13, 
14, 31-34] RASFs characteristically show a resistance to apoptosis.[35] We have analyzed the 
effect of SIRT1 on apoptosis in RASFs. We found that overexpression of SIRT1 protected 
cells from apoptosis. The antiapoptotic effect of SIRT1 together with its constitutive high 
expression levels in RA suggest that SIRT1 may contribute to the apoptosis resistant 
phenotype seen in RASFs.  
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 Up to now, published data on the effects of SIRT1 on inflammation is controversial. 
Macrophages from myeloid SIRT1 knock out mice displayed increased NF-κB mediated 
inflammation in response to environmental stress, indicating an anti-inflammatory activity of 
SIRT1.[16] In agreement, a sirtuin activator had an inhibitory effect on LPS induced 
inflammation in intraperitoneal murine macrophages.[36] However, the biological effects 
mediated by SIRT1 seem to differ between cell types. It has been shown that the beneficial 
effects of calorie restriction induced SIRT1 in white adipose tissue or skeletal muscle cells 
were not seen in liver tissues.[37] A previous report using RA synovial biopsy explants 
showed that treatment with nicotinamide, a non-specific inhibitor of sirtuins, resulted in a 
reduction of IL-6 and TNF-α secretion, suggesting that the sirtuin family may have 
proinflammatory effects.[17] In line with this finding, it was recently reported that the 
proinflammatory cytokine HMGB1 stimulated production of TNF-α through activation of 
TLR4 in periodontal cells. This TLR4 dependent enhanced expression of TNF-α was blocked 
when SIRT1 or NF-κB were inhibited.[38] As we have previously shown that TLR activation 
results in upregulation of NAD+ producing PBEF/Visfatin and as SIRT1 activity is NAD+ 
dependent [4, 6, 39, 40], it is conceivable that TLR4 stimulation of synovial cells during 
chronic arthritis induces SIRT1 activity and that SIRT1 in a NF-κB dependent fashion 
prolongs the life-span of RASFs and enhances the proinflammatory cytokine production. 
Endogenous TLR4 ligands such as heat shock proteins, HMGB1 and others have been 
described, however, it is not known which of these are disease relevant in RA [41]. In our 
detailed analysis of the effects of SIRT1 on cytokine production in RASFs and monocytes, we 
found that overexpression of SIRT1 had a modulatory effect on IL-6 and TNF-α production in 
RASFs and monocytes, respectively, resulting in a significant induction of these cytokines in 
a NF-κB dependent fashion. These enhancing effects on cytokine expression were not seen 
when cells were transfected with an enzymatically inactive mutant form of SIRT1, which 
would argue that higher wild type SIRT1 expression levels may support the production of 
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 proinflammatory cytokines. Interestingly, the pan sirtuin inhibitor Sirtinol also reduced 
proinflammatory cytokines similar to the SIRT1 specific inhibitor EX-527, suggesting that the 
overall inhibition of sirtuins may have an anti-inflammatory effect. 
In summary, we report the overexpression of SIRT1 in RA synovial tissue and despite 
evidence for an anti-inflammatory role of SIRT1 in animal models of inflammation we show 
that SIRT1 directly enhances proinflammatory cytokine production of synovial cells. 
Cytokine production is further potentiated by an anti-apoptotic effect prolonging the life span 
of RASFs. Our results suggest that careful investigation of the cell and disease specific effects 
of sirtuins is necessary to delineate possible therapeutic uses of agents targeting these 
molecules. 
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 FIGURE LEGENDS 
Figure 1: High basal protein and mRNA levels of SIRT1 in tissues, synovial fibroblasts and 
monocytes from RA patients. 
(A) Western blot showing the basal expression of SIRT1 protein from patients with RA and 
OA in synovial tissue samples (n=4, each) or in synovial fibroblasts (n=3, each). α-tubulin 
served as loading control. (B) Relative expression units of SIRT1 mRNA in synovial 
fibroblasts from patients with RA (n=7) or OA (n=4) and in monocytes from patients with RA 
(n=7) or healthy controls (n=6) are shown. Results are presented as the difference in threshold 
cycle [delta Ct], relative to 18S rRNA. See Table 1 for patient characteristics. 
* = p<0.01, unpaired t-test. 
 
Figure 2: SIRT1 expression in synovial tissues from RA patients. 
(A) Representative sections of RA synovial tissue specimens stained for SIRT1 or IgG 
control. Positive staining of SIRT1 appears as dark gray. Sections were counterstained with 
Eosin. (B) Representative sections of RA synovial tissue specimens double-labeled for SIRT1 
and vimentin or IgG control. SIRT1 appears as dark gray, and vimentin as red. (C) 
Representative sections of RA synovial tissue specimens double-labeled for SIRT1 and CD68 
or IgG control. SIRT1 appears as dark gray, and CD68 as red. 
One representative section is shown (n=4). Original magnification x400.  
 
Figure 3: SIRT1 is induced upon stimulation with TNF-α. 
(A) RASFs were treated with different TLR ligands (300 ng/ml Pam3CSK4, 10 μg/ml poly 
(I:C), 10 ng/ml LPS) and two major RA cytokines (10 ng/ml TNF-α, 1 ng/ml IL-1β) for 24 
hours (n=7-9). Changes in SIRT1 mRNA levels relative to untreated RASFs are shown [x-
fold]. (B) Representative Western blots confirming induction of SIRT1 protein upon 
stimulation of RASFs with TNF-α for 48 hours (n=3). (C) Monocytes from healthy 
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 individuals (n=5-8) were treated with 10 ng/ml TNF-α for the indicated time points and 
SIRT1 mRNA levels relative to untreated cells are shown[x-fold]. 
* = p<0.05, by ANOVA followed by Dunnett’s post-test. 
 
Figure 4: SIRT1 mediates apoptosis resistance in RASFs. 
RASFs were transfected with SIRT1 specific siRNA (n=7) or with a vector encoding wild 
type SIRT1 (n=3) for 72 hours. Flow cytometry was used to measure levels of AnnexinV and 
PI positive cells relative to control siRNA (ctr) or mock (empty vector) transfected RASFs. 
Values are relative changes in the number of AnnexinV or PI positive cells compared to 
control transfected cells [x-fold],.* = p<0.05, by paired t-test. 
 
Figure 5: Increased levels of proinflammatory cytokines in RASFs and monocytes 
overexpressing SIRT1. 
(A) RASFs were transfected with expression vectors encoding wild type (n=8) and mutant 
(n=8) forms of SIRT1. IL-6 protein concentrations were measured in culture supernatants at 
40 hours post-transfection. (B) RASFs (n=5) were transfected with control siRNA (ctr) or 
SIRT1 specific siRNA (si1) for 48 hours and stimulated with 10 ng/ml LPS for another 24 
hours. Basal and LPS induced production of IL-6 and IL-8 was measured in culture 
supernatants. (C) Primary peripheral monocytes from healthy individuals were transfected to 
overexpress wild type or mutant SIRT1 (n=8) and LPS induced TNF-α production in the 
supernatants was measured. (D) Monocytes (n=6) were transfected with control siRNA (ctr) 
or with SIRT1 siRNA (siSIRT1). LPS induced production of TNF-α in culture supernatants is 
shown. 
Values are means ± SEM. * = p<0.05, by paired t-test. 
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 Figure 6: Inhibition of the activity of SIRT1 by enzymatic inhibitors results in reduced levels 
of TNF-α. 
(A) Monocytes from healthy individuals (n=9) were stimulated with 10 ng/ml LPS for 24 
hours in presence or absence of the SIRT1 specific inhibitor EX-527 (9 μM). Concentrations 
of TNF-α were measured in the culture supernatants (B) Monocytes (n=7) were stimulated 
with 10 ng/ml LPS in presence of the pan sirtuin inhibitor Sirtinol (30 μM) for 24 hours and 
the levels of TNF-α were measured. 
Results are shown as means ± SEM. * = p<0.05, by paired t-test. 
 
Figure 7: SIRT1 mediates its proinflammatory effects through NF-κB. 
Primary human monocytes from healthy volunteers (n=4) were transfected to overexpress 
wild type SIRT1 or were mock transfected and stimulated with 10 ng/ml LPS in presence or 
absence of an inhibitor of IKK-2, sc-514 (50 μM, in DMSO). The production of TNF-α was 
measured in the culture supernatants. Results are shown as means ± SEM. * = p<0.05, by 
paired t-test. 
 
Supplementary Figure 1: Time course analysis of TNF-α induced SIRT1 expression. 
RASF (n=5-8) were treated with 10 ng/ml TNF-α for 1, 4 and 8 hours. Levels of SIRT1 
mRNA were measured by RT-PCR and are shown as fold induction relative to untreated cells 
[x-fold].  
* = p<0.05, by ANOVA followed by Dunnett’s post-test. 
 
Supplementary Figure 2: Increased levels of TNF-α induced IL-6 production in RASFs 
overexpressing SIRT1. 
RASFs (n=9) were transfected with SIRT1 wild type expression vector or an empty vector 
control (mock) and stimulated with 10 ng/ml TNF-α. IL-6 protein production was measured 
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in culture supernatants at 40 hours post-transfection. Induction in IL-6 production is displayed 
relative to mock transfected cells. Values are means ± SEM. * = p<0.05, by paired t-test. 
 
Supplementary Figure 3: Confirmation of successful transfection with wild type or mutant 
SIRT1 and siRNA targeting SIRT1 in primary monocytes and RASFs. 
RASFs were transfected with vectors encoding wild type and mutant SIRT1 (A) or SIRT1 
specific siRNA (B) Monocytes from healthy individuals were transfected with wild type or 
mutant SIRT1 plasmids (C) or siRNA targeting SIRT1 (D).  
SIRT1 mRNA relative expression units are presented as the difference in threshold cycle 
[delta Ct], relative to 18S rRNA. Values are means ± SEM. * = p<0.05, by paired t-test. 
 
Supplementary Figure 4: Knockdown of SIRT1 reduced mRNA levels of proinflammatory 
cytokines. 
RASFs (n=3) were transfected with control siRNA (ctr) or with SIRT1 siRNA (siSIRT1) for 
48 hours and then stimulated with 10 ng/ml LPS for another 24 hours. Basal and LPS induced 
relative changes in mRNA levels for IL-6 (A) and IL-8 (B) are shown, compared to control 
transfected cells [x-fold].  
Values are means ± SEM. * = p<0.05, by paired t-test. 
